Literature DB >> 2323806

Chemotactic response of human monocytes to pentapeptide analog derived from immunodeficiency virus protein gp 120.

S Spisani1, R Gavioli, A L Giuliani, T Cavalletti, M Marastoni, G Balboni, S Salvadori, R Tomatis, S Traniello.   

Abstract

The octapeptide sequence of peptide T is contained within the envelope of HIV and seems to mediate the viral binding to CD4 expressing cells, including monocytes. The biological activity of the alpha-aminobutyric acid pentapeptide derived from the C-terminal sequence of peptide T, in which the polar side chain of threonine in position 4 is substituted by a hydrophilic group, is measured by the monocyte chemotaxis assay. The chemotactic activity of human monocytes is assessed by determining the concentration at which the pentapeptide analog is maximally active and the effectiveness at that concentration, in comparison with peptide T and two shorter homologs, the pentapeptide and tetrapeptide. These experiments suggest that the synthetic analog is a potent chemotactic factor active at picomolar concentrations and that it competes with peptide T for the monocyte binding site.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2323806     DOI: 10.1007/bf00914029

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  13 in total

1.  A synthetic peptide homologous to the envelope proteins of retroviruses inhibits monocyte-mediated killing by inactivating interleukin 1.

Authors:  E S Kleinerman; L B Lachman; R D Knowles; R Snyderman; G J Cianciolo
Journal:  J Immunol       Date:  1987-10-01       Impact factor: 5.422

2.  Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity.

Authors:  C B Pert; J M Hill; M R Ruff; R M Berman; W G Robey; L O Arthur; F W Ruscetti; W L Farrar
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

3.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

4.  Structure-activity relationships of peptide T-related pentapeptides.

Authors:  M Marastoni; S Salvadori; G Balboni; S Spisani; R Gavioli; S Traniello; R Tomatis
Journal:  Arzneimittelforschung       Date:  1989-08

5.  CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship to vasoactive intestinal polypeptide.

Authors:  M R Ruff; B M Martin; E I Ginns; W L Farrar; C B Pert
Journal:  FEBS Lett       Date:  1987-01-19       Impact factor: 4.124

6.  AIDS: a syndrome of immune dysregulation, dysfunction, and deficiency.

Authors:  A S Edelman; S Zolla-Pazner
Journal:  FASEB J       Date:  1989-01       Impact factor: 5.191

7.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

8.  Conformational studies of synthetic tripeptide chemoattractants.

Authors:  G Vertuani; S Spisani; M Boggian; S Traniello; A Scatturin
Journal:  Int J Pept Protein Res       Date:  1987-04

9.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

10.  Leukocyte locomotion and chemotaxis. New methods for evaluation, and demonstration of a cell-derived chemotactic factor.

Authors:  S H Zigmond; J G Hirsch
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  1 in total

1.  Modulation of neutrophil functions by activated platelet release factors.

Authors:  S Spisani; A L Giuliani; T Cavalletti; M Zaccarini; L Milani; R Gavioli; S Traniello
Journal:  Inflammation       Date:  1992-04       Impact factor: 4.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.